ABEONA THERAPEUTICS INC
NASDAQ: ABEO (Abeona Therapeutics Inc.)
Kemas kini terakhir: 2 jam lalu6.00
0.00 (0.00%)
| Penutupan Terdahulu | 6.00 |
| Buka | 6.02 |
| Jumlah Dagangan | 406,216 |
| Purata Dagangan (3B) | 1,691,780 |
| Modal Pasaran | 306,940,192 |
| Harga / Jualan (P/S) | 37.76 |
| Harga / Buku (P/B) | 7.72 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Aug 2025 - 15 Aug 2025 |
| EPS Cair (TTM) | -0.630 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 57.92% |
| Nisbah Semasa (MRQ) | 4.90 |
| Aliran Tunai Operasi (OCF TTM) | -59.88 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -39.71 M |
| Pulangan Atas Aset (ROA TTM) | -49.95% |
| Pulangan Atas Ekuiti (ROE TTM) | -271.78% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Abeona Therapeutics Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | 0.0 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.50 |
|
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 6.14% |
| % Dimiliki oleh Institusi | 63.16% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Suvretta Capital Management, Llc | 31 Mar 2025 | 3,685,503 |
| Nantahala Capital Management, Llc | 31 Mar 2025 | 3,509,850 |
| Western Standard Llc | 31 Mar 2025 | 2,281,199 |
| Vivo Capital, Llc | 31 Mar 2025 | 1,842,751 |
| Rosalind Advisors, Inc. | 31 Mar 2025 | 1,805,817 |
| Laurion Capital Management Lp | 31 Mar 2025 | 1,306,589 |
| Propel Bio Management, Llc | 31 Mar 2025 | 624,022 |
| Kennedy Capital Management Llc | 31 Mar 2025 | 621,763 |
| Ikarian Capital, Llc | 31 Mar 2025 | 533,581 |
| Citigroup Inc | 31 Mar 2025 | 527,558 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 20.00 (HC Wainwright & Co., 233.33%) | Beli |
| 20.00 (Stifel, 233.33%) | Beli | |
| Median | 20.00 (233.33%) | |
| Rendah | 19.00 (Oppenheimer, 216.67%) | Beli |
| Purata | 19.67 (227.83%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 6.31 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Oppenheimer | 02 Jun 2025 | 19.00 (216.67%) | Beli | 6.28 |
| Stifel | 16 May 2025 | 20.00 (233.33%) | Beli | 6.10 |
| HC Wainwright & Co. | 30 Apr 2025 | 20.00 (233.33%) | Beli | 6.56 |
| 24 Mar 2025 | 15.00 (150.00%) | Beli | 5.12 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| O'MALLEY BRENDAN M. | - | 6.74 | -10,470 | -70,568 |
| SESHADRI VISHWAS | - | 6.74 | -50,676 | -341,556 |
| VAZZANO JOSEPH WALTER | 6.48 | 6.74 | -4,462 | -33,540 |
| Jumlah Keseluruhan Kuantiti Bersih | -65,608 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -445,665 | |||
| Purata Pembelian Keseluruhan ($) | 6.48 | |||
| Purata Jualan Keseluruhan ($) | 6.74 | |||
| Julat Insider ($) | ||||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| O'MALLEY BRENDAN M. | Pegawai | 06 Jun 2025 | Jual (-) | 10,470 | 6.74 | 70,568 |
| SESHADRI VISHWAS | Pegawai | 06 Jun 2025 | Jual (-) | 50,676 | 6.74 | 341,556 |
| VAZZANO JOSEPH WALTER | Pegawai | 06 Jun 2025 | Jual (-) | 17,795 | 6.74 | 119,938 |
| VAZZANO JOSEPH WALTER | Pegawai | 05 Jun 2025 | Diperolehi (+) | 13,333 | 6.48 | 86,398 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |